Meeting
2024 ASCO Annual Meeting
Trends in prices of checkpoint inhibitors in the US, 2016-2023.
Authors
Jeddeo Paul
Brigham and Women's Hospital, Boston, MA
Jeddeo Paul , Aaron Philip Mitchell , Aaron S Kesselheim , Benjamin N Rome
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Quality Care/Health Services Research
Track
Care Delivery and Quality Care
Sub Track
Health Services Research
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 11075)
DOI
10.1200/JCO.2024.42.16_suppl.11075
Abstract #
11075
Poster Bd #
270
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Evaluation of toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer (NSCLC).
First Author: Rathi Narayana Pillai
Poster
2021 Gastrointestinal Cancers Symposium
Response to PD-1 and PD-L1 based immunotherapy in MSS advanced colorectal cancer is impacted by metastatic disease sites.
First Author: Marwan Fakih
Poster
2020 ASCO Virtual Scientific Program
A phase II, open-label study of tomivosertib (eFT508) added on to continued checkpoint inhibitor therapy in patients (pts) with insufficient response to single-agent treatment.
First Author: Anthony B. El-Khoueiry
Poster
2018 ASCO Annual Meeting
Association of STK11/LKB1 mutations with primary resistance to PD-1/PD-L1 axis blockade in PD-L1 positive non-squamous NSCLC.
First Author: Ferdinandos Skoulidis